About Connexome
Technological innovations including machine learning and AI are driving the next developments in life sciences and health care.
Bringing together omics (genomics, epigenomics, transcriptomics, metabolomics) technologies with real world data offers huge potential for the development of new diagnostic and therapeutic products in precision medicine.
We are dedicated to providing innovative solutions for integrating multi-omics data with real world evidence and AI to drive precision medicine forward.
We work with pharmaceutical companies, academic institutions, and healthcare organizations to deliver cutting-edge solutions that drive innovation in precision medicine. Contact us today to learn more about how we can help advance your research and improve patient outcomes.
Martin Seifert
(Founder and CEO)
I am an entrepreneur, accomplished general manager and operational leader in the life science industry. I enjoy building innovation driven business strategies and leading projects teams.
Data integration machine learning and AI are driving the next developments in life sciences. Bringing together omics (genomics, epigenomics, transcriptomics, metabolomics) technologies with real world data offers huge potential for the discovery of next generation biomarkers and precision medicine.
However, bringing the right people from different disciplines together is even more important than fulfilling the technical requirements.
We are currently working with teams in academia, biotech companies, pharma industry and large clinic clusters assisting them to accomplish the mission of precision healthcare.
We are scientists by heart but we also know that commercial success always requires to fulfill customers’ demands and to keep highest quality standards. These are key issues in translational success in life science and the healthcare environment.
You can find my professional profile on linkedin: linkedin.com/in/martin-seifert-connexome
Papers and patents.
See all my publications on google scholar:
Selected publications and patents:
Plasma Metabolome Signature Indicative of BRCA1 Germline Status Independent of Cancer Incidence
J Penkert, A Märtens, M Seifert, B Auber, K Derlin, U Hille-Betz, …
Frontiers in oncology 11, 627217
A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome
Marc Sultan, Marcel H Schulz, Hugues Richard, Alon Magen, Andreas Klingenhoff, Matthias Scherf, Martin Seifert, Tatjana Borodina, Aleksey Soldatov, Dmitri Parkhomchuk, Dominic Schmidt, Sean O’Keeffe, Stefan Haas, Martin Vingron, Hans Lehrach, Marie-Laure Yaspo
Science 321 (5891), 956-960
Detecting and visualizing gene fusions
J Supper, C Gugenmus, J Wollnik, T Drueke, M Scherf, A Hahn, K Grote, …M Seifert
Methods 59 (1), S24-S28
A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men
G Petrovics, H Li, T Stümpel, SH Tan, D Young, S Katta, Q Li, K Ying, ..M Seifert…EBioMedicine 2 (12), 1957-1964 EBioMedicine is the premium gold open access venue for translational biomedical research, published by The Lancet
Prostate cancer gene profiles and methods of using the same
SK Srivastava, A Dobi, G Petrovics, T Werner, M Seifert, M Scherf Patent
Genomic rearrangements associated with prostate cancer and methods of using the same
SK Srivastava, A Dobi, G Petrovics, T Werner, M Seifert, M Scherf Patent
The International Human Epigenome Consortium: a blueprint for scientific collaboration and discovery
HG Stunnenberg, S Abrignani, D Adams, M de Almeida, L Altucci, V Amin, …M Seifert …Cell 167 (5), 1145-1149
BLUEPRINT to decode the epigenetic signature written in blood
D Adams, L Altucci, SE Antonarakis, J Ballesteros, S Beck, A Bird, C Bock, …M Seifert…Nature biotechnology 30 (3), 224-226
Whole genome and transcriptome analyses of environmental antibiotic sensitive and multi‐resistant Pseudomonas aeruginosa isolates exposed to waste water …T Schwartz, O Armant, N Bretschneider, A Hahn, S Kirchen, M Seifert, …Microbial Biotechnology 8 (1), 116-130
Leveraging cross-species transcription factor binding site patterns: from diabetes risk loci to disease mechanisms
M Claussnitzer, SN Dankel, B Klocke, H Grallert, V Glunk, T Berulava, …M Seifert …
Cell 156 (1-2), 343-358
Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression CA Derosa, B Furusato, S Shaheduzzaman, V Srikantan, Z Wang, Y Chen, …M Seifert…Prostate cancer and prostatic diseases 15 (2), 150-156
LSAMP gene deletion is associated with rapid disease progression in prostate cancer of African American men
A Dobi, G Petrovics, H Li, SH Tan, T Stümpel, D Young, S Katta, Q Li, … M Seifert...Cancer Research 76 (14 Supplement), 140-140
5-Hydroxymethylcytosine remodeling precedes lineage specification during differentiation of human CD4+ T cells
CE Nestor, A Lentini, CH Nilsson, DR Gawel, M Gustafsson, L Mattson, …M Seifert…Cell reports 16 (2), 559-570
Detecting estrogens in food and the environment B Hock, M Seifert
Nature Biotechnology 17 (12), 1162-1163